ClinicalTrials.gg
CompletedNCT00401973Updated Oct 6, 2009Results posted

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

A Phase 3 interventional study of olanzapine and amantadine in Schizophrenia and Schizoaffective Disorders, sponsored by Eli Lilly and Company. Completed at 15 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-10-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
34th of 94
199 · median 114
Started
2006
with 8 others
Phase 3
25 of 97
1 open now
Registered
43rd of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 34th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2006, is one of 25 in phase 3, and was the 43rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The goal of this study is to answer the following questions:

  • Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine
  • Whether taking amantadine, metformin or zonisamide can help patients decrease or eliminate some of the changes in body that occur with weight gain
  • How weight gain associated with olanzapine can affect people
  • Whether treatment with amantadine, metformin or zonisamide can help eliminate weight gain associated with olanzapine and not interfere with the positive effects of olanzapine on functioning of people with schizophrenia and other diseases
03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must have been diagnosed with schizophrenia or schizoaffective disorder
  • You must be able to visit the doctor's office once every two weeks for three months, then once every four weeks for the next three months with a possible bi-weekly visit during the fifth month
  • If you are currently taking a medication for schizophrenia or schizoaffective disorder, you have been taking it for at least 30 days without any changes
  • If you are a female, you must have a negative pregnancy test and be using an effective method of

Exclusion criteria

Exclusion Criteria:

  • You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack, stroke, uncontrolled seizures, serious infection, unstable heart disease (such as ischemic heart disease or congestive heart failure), an uncorrected narrow angle glaucoma or (HIV)
  • You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine systems, or blood
  • You have a diagnosis of an eating disorder
  • You have a history of Parkinson's Disease or any related disorders
  • You are allergic to sulfa drugs or any of the medications involved in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Olanzapine

    olanzapine plus behavioral information

    Drug: olanzapine · Behavioral: Wellness education

  • Experimental
    Olanzapine + Amantadine

    Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information

    Drug: olanzapine · Drug: amantadine · Drug: metformin · Drug: zonisamide · Behavioral: Wellness education

  • Experimental
    Olanzapine + Metformin

    Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information

    Drug: olanzapine · Drug: amantadine · Drug: metformin · Drug: zonisamide · Behavioral: Wellness education

Interventions

  • 5-20 milligrams (mg), oral, daily for 22 weeks.

    Also known as: LY170053, Zyprexa

  • Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.

  • Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.

  • Zonisamide, 100-400mg, oral, daily.

  • BehavioralWellness education

    weight management

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint in Weight

    Time frame: Baseline to endpoint (22 weeks)

Secondary outcomes

  1. Mean Change From Baseline to Endpoint in Fasting Triglycerides

    Time frame: Baseline to endpoint (22 weeks)

  2. Mean Change From Baseline to Endpoint in Fasting Total Cholesterol

    Time frame: Baseline to endpoint (22 weeks)

  3. Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol

    Time frame: Baseline to endpoint (22 weeks)

  4. Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol

    Time frame: Baseline to endpoint (22 weeks)

  5. Mean Change From Baseline to Endpoint in Fasting Glucose

    Time frame: Baseline to endpoint (22 weeks)

  6. Mean Change From Baseline to Endpoint in Hemoglobin A1c

    Time frame: Baseline to endpoint (22 weeks)

  7. Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score

    The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.

    Time frame: Baseline to endpoint (22 weeks)

  8. Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline to endpoint (22 weeks)

  9. Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)

    Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline to endpoint (22 weeks)

  10. Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks

    To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.

    Time frame: Baseline to endpoint (22 weeks)

07

Results

Posted Sep 30, 2009

Participant flow

Participant flow — Overall Study
MilestoneOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Started507673
Completed395050
Not completed112623
Withdrew: Adverse event284
Withdrew: Clinical relapse011
Withdrew: Lack of efficacy003
Withdrew: Lost to follow-up222
Withdrew: Physician decision201
Withdrew: Protocol violation123
Withdrew: Sponsor decision010
Withdrew: Withdrawal by subject4129

Outcome measures

PrimaryChange From Baseline to Endpoint in Weight
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Least squares mean · kilograms
Change From Baseline to Endpoint in Weight
kilogramsOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Change From Baseline to Endpoint in Weight2.76 ± 0.752.40 ± 0.650.65 ± 0.63
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · Mixed Models Analysis · p = 0.065 (P-value for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)Repeated Measures Analysis
  • Olanzapine vs Olanzapine + Amantadine · Mixed Models Analysis · p = 0.113Repeated Measures Analysis
  • Olanzapine vs Olanzapine + Metformin · Mixed Models Analysis · p = 0.036Repeated Measures Analysis
SecondaryMean Change From Baseline to Endpoint in Fasting Triglycerides
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · millimoles per Liter (mmol/L)
Mean Change From Baseline to Endpoint in Fasting Triglycerides
millimoles per Liter (mmol/L)OlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline1.58 ± 0.811.61 ± 0.761.68 ± 1.00
Change from Baseline0.33 ± 1.010.35 ± 0.880.06 ± 0.64
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.498 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.637 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.125 (P-value for Change from Baseline.)
SecondaryMean Change From Baseline to Endpoint in Fasting Total Cholesterol
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · millimole per Liter (mmol/L)
Mean Change From Baseline to Endpoint in Fasting Total Cholesterol
millimole per Liter (mmol/L)OlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline5.01 ± 1.005.03 ± 1.094.91 ± 1.21
Change from Baseline0.36 ± 0.840.01 ± 1.06-0.08 ± 0.92
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.173 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.016 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.029 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
SecondaryMean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · millimole per liter (mmol/L)
Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol
millimole per liter (mmol/L)OlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline1.25 ± 0.291.26 ± 0.361.22 ± 0.35
Change from Baseline-0.00 ± 0.23-0.11 ± 0.25-0.08 ± 0.24
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.017 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.015 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.071 (P-value for Change from Baseline.)
SecondaryMean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · millimole per Liter (mmol/L)
Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol
millimole per Liter (mmol/L)OlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline3.02 ± 0.883.06 ± 1.032.91 ± 0.93
Change from Baseline0.16 ± 0.60-0.04 ± 0.95-0.02 ± 0.84
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.152 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.350 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.123 (P-value for Change from Baseline.)
SecondaryMean Change From Baseline to Endpoint in Fasting Glucose
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · millimole per Liter (mmol/L)
Mean Change From Baseline to Endpoint in Fasting Glucose
millimole per Liter (mmol/L)OlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline5.32 ± 0.465.25 ± 0.785.28 ± 0.63
Change from Baseline0.26 ± 0.990.10 ± 0.480.01 ± 0.58
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.499 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.833 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.339 (P-value for Change from Baseline.)
SecondaryMean Change From Baseline to Endpoint in Hemoglobin A1c
Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · percent hemoglobin A1c
Mean Change From Baseline to Endpoint in Hemoglobin A1c
percent hemoglobin A1cOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline5.51 ± 0.465.48 ± 0.395.53 ± 0.37
Change from Baseline0.09 ± 0.450.10 ± 0.37-0.03 ± 0.25
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.278 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.976 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.049 (P-value for Change from Baseline.)
SecondaryChange From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score

The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126.

Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score
units on a scaleOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline48.24 ± 15.9845.90 ± 12.4447.00 ± 14.18
Change from Baseline-13.89 ± 18.61-9.90 ± 11.24-9.72 ± 14.15
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.122 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.225 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.124 (P-value for Change from Baseline.)
SecondaryChange From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
units on a scaleOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline12.76 ± 8.0814.22 ± 11.1415.40 ± 9.21
Change from Baseline-6.39 ± 8.37-4.12 ± 7.20-4.36 ± 7.47
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.020 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.037 (P-value for Change from Baseline)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.038 (P-value for Change from Baseline.)
SecondaryChange From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)

Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)
units on a scaleOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
Baseline4.06 ± 1.244.03 ± 1.074.00 ± 1.13
Change from Baseline-0.98 ± 1.13-0.72 ± 1.14-0.79 ± 1.03
Statistical analysis
  • Olanzapine vs Olanzapine + Amantadine vs Olanzapine + Metformin · ANCOVA · p = 0.474 (P-value for Change from Baseline for Olanzapine versus pooled olanzapine+amantadine and olanzapine+metformin.)
  • Olanzapine vs Olanzapine + Amantadine · ANCOVA · p = 0.404 (P-value for Change from Baseline.)
  • Olanzapine vs Olanzapine + Metformin · ANCOVA · p = 0.652 (P-value for Change from Baseline)
SecondaryCorrelations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks

To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups.

Time frame:
Baseline to endpoint (22 weeks)
Reported as:
Number · correlation
Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks
correlation2 Weeks22 Weeks
EI: Disinhibition-0.0340.285
EI: Cognitive Restraint-0.273-0.038
EI: Hunger-0.1500.148
FCI: Carbohydrates/Starches (N=186, N=141)0.013-0.064
FCI: Fast Food Fats (N=188, N=140)-0.0190.047
FCI: High Fats (N=186, N=138)0.0510.043
FCI: Sweets (N=187, N=140)0.022-0.008
FCI: Total Score (N=184, N=137)0.039-0.000

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine———
Olanzapine + Amantadine———
Olanzapine + Metformin———
Most frequent serious events
Most frequent serious events
EventOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
SchizophreniaPsychiatric disorders3/500/760/73
HallucinationPsychiatric disorders0/501/762/73
Psychotic disorderPsychiatric disorders1/500/760/73
Suicidal ideationPsychiatric disorders1/500/760/73
Chest painGeneral disorders0/500/761/73
Suicide attemptPsychiatric disorders0/500/761/73
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/501/760/73
AkathisiaNervous system disorders0/501/760/73
Panic attackPsychiatric disorders0/501/760/73
Most frequent other events
Showing 10 of 20
Most frequent other events
EventOlanzapineOlanzapine + AmantadineOlanzapine + Metformin
DiarrhoeaGastrointestinal disorders0/503/7610/73
SomnolenceNervous system disorders4/505/768/73
InsomniaPsychiatric disorders5/504/761/73
NauseaGastrointestinal disorders2/503/765/73
VomitingGastrointestinal disorders0/501/765/73
Increased appetiteMetabolism and nutrition disorders3/501/763/73
Weight increasedInvestigations2/504/764/73
HeadacheNervous system disorders2/502/764/73
Dry mouthGastrointestinal disorders2/504/760/73
NasopharyngitisInfections and infestations0/504/760/73

Baseline characteristics

Age Continuous
Age Continuous(years)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
Mean38.7 ± 12.8938.2 ± 11.4038.7 ± 12.0138.5 ± 11.95
Sex: Female, Male
Sex: Female, Male(Participants)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
Female19303079
Male314643120
Region of Enrollment
Region of Enrollment(participants)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
United States13222156
Mexico791127
Puerto Rico58518
Israel58922
Russian Federation11151440
Korea, Republic of9141336
Race/Ethnicity
Race/Ethnicity(participants)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
African210416
Caucasian23303487
East Asian10151439
Hispanic14201852
Native American0011
West Asian1124
Type of Diagnosis
Type of Diagnosis(participants)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
Schizoaffective8151841
Schizophrenia426155158
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meter (kg/m^2))OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
Mean27.0 ± 4.5327.3 ± 4.6727.0 ± 4.8427.1 ± 4.68
Onset Age
Onset Age(years)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
Mean24.35 ± 8.4226.44 ± 9.9824.40 ± 9.1825.15 ± 9.32
Previous Number of Episodes
Previous Number of Episodes(number of episodes)OlanzapineOlanzapine + AmantadineOlanzapine + MetforminTotal
Mean1.53 ± 1.022.19 ± 5.902.22 ± 5.772.04 ± 5.06

1 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    National City, California 91950, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Canton, Ohio 44708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johnson City, Tennessee 37614, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38105, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Desoto, Texas 75115, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio De Janeiro, 21020-130, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salvador, 40301500, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beer Yaacov, 70350, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 143-711, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 14050, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bayamon, 00961, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00717, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00907, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 117603, Russian Federation
09

References and documents

Publications

  • Hoffmann VP, Case M, Jacobson JG. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry. 2012 Feb;73(2):216-23. doi: 10.4088/JCP.09m05580. Epub 2011 May 17. PubMed 21672497 ↗
  • Case M, Treuer T, Karagianis J, Hoffmann VP. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry. 2010 Sep 14;10:72. doi: 10.1186/1471-244X-10-72. PubMed 20840778 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2006
First posted
Nov 22, 2006
Start
Nov 2006
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Sep 30, 2009
Last update
Oct 6, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00401973
First posted
Nov 22, 2006
Start date
Nov 2006
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Sep 30, 2009
Last update
Oct 6, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion